Latest Breaking News On - Williamh collier - Page 1 : comparemela.com

Arbutus to Participate in Three Upcoming Investor Conferences

06.02.2023 - WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral .

Arbutus Announces Resignation of Board Member

WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging.

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update - read this article along with other careers information, tips and advice on BioSpace

Arbutus to Present at Jefferies London Healthcare Conference

08.11.2022 - WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral .